Skip to main content

Table 1 Demographic and clinical measures in cases and controls. For cases and controls categorical variables are presented as percentage of patients; chi-square test was used for group differences; and continuous variables are presented as mean values (standard deviation) or *median values (25/75th interquartiles) because of skewed distribution. The p values were obtained by *Mann-Whitney test. #: data for 913 patients for ejection fraction, data for 200 controls/1026 patients for apoA-I and apoB, for 200 controls/905 patients for Hs-CRP, and for 200 controls/1060 patients for Lp(a).

From: Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease

Variable

Cases n = 1102

Controls n = 444

P- value

Age, years

61.1 (10.1)

59.7 (7.4)

<0.001

BMI, kg/m2

27.2 (3.7)

26.7 (4.3)

0.02

Sex, male %

74.7

72.7

0.43

Current smoking, %

27.3

11.0

< 0.001

Diabetes mellitus, %

21.6

3.7

<0.001

Hypertension, %

71.9

28.6

<0.001

Family history of CAD, %

38.2

20.1

<0.001

Statins, %

35.8

6.3

< 0.001

ACE inhibitors, %

47.8

8.3

<0.001

Angiotensin receptor blockers, %

5.0

3.8

0.327

Ejection fraction <40%#, %

7.6

-

-

Hs-CRP*, mg/l#

4.4 (1.9/12.4)

1.5 (0.9/3.8)

<0.001

PLTP, U/l

25.5 (9.8)

22.4 (7.4)

<0.001

CETP, U/l

49.9 (20.9)

41.4 (17.4)

<0.001

Total cholesterol, mg/dl

219.7 (45.7)

238.4 (41.8)

<0.001

LDL cholesterol, mg/dl

141.0 (40.1)

155.5 (35.1)

<0.001

HDL cholesterol, mg/dl

48.8 (14.7)

59.4 (15.9)

<0.001

Triglyceride*, mg/dl

141 (102/193)

120 (87/167)

<0.001

Apolipoprotein A-I, g/l#

1.31 (0.24)

1.62 (0.28)

<0.001

Apolipoprotein B, g/l#

1.20 (0.28)

1.19 (0.23)

0.3

Lipoprotein(a), mg/dl#

36.3 (38.9)

24.2 (30.4)

<0.001